PROSPECTS FOR IMPROVING THE TREATMENT EFFICACY FOR PATIENTS WITH MULTIDRUG RESISTANT TUBERCULOSIS: GLOBAL TRENDS AND NATIONAL ADVANCES

Authors

  • Yu. I. Feshchenko State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»
  • N. A. Lytvynenko State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»
  • H. O. Varytska State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»
  • O. P. Chobotar State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»
  • M. V. Pohrebna State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»
  • Yu. O. Senko State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»
  • V. V. Davydenko State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»
  • L. V. Shcherbakova State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»
  • N. Hrankina State Establishment «F. Yanovskyi National Institute of Phthi­sio­logy and Pulmonology National Academy of Medical Sciences of Ukraine»

DOI:

https://doi.org/10.11603/1681-2727.2017.4.8418

Keywords:

multidrug resistant tuberculosis, tuberculosis with extensively drug resistance, treatment efficacy, short antimycobacterial regimen, linzolid.

Abstract

The Aim of work. Study the effectiveness of treatment among patients with multidrug resistant and extensively drug resistant tuberculosis using standard approaches for conventional antimycobacterial therapy and to present the first results of the efficacy of adapted to the Ukrainian conditions, short 12-month anti­myco­bacterial therapy with the inclusion of linzolid.

Materials and methods. In general, the design of the work included several types of researches. In a retrospective cohort study the efficacy of treatment among 1038 patients with MDR TB and XDR TB was studied over the period from 2006 to 2015. In a prospective clinical case-control study the effectiveness of the short 12-month antimycobacterial regimens among 150 patients with new MDR TB cases, including those with fluoroquinolone or aminoglycoside / polypeptide resistance over the period from 2015 to 2016 was inquired. The abbreviated 12-month regimens of AMBT for patients with MRTB and pre-RRTB included at least 6 effective PTPs: pyrazinamide, kanamyсin / capreomycin, levofloxacin / moxifloxacin, protionamid, cycloserine, linezolid and high doses of isoniazid.

References

Melnyk, V.M., Novozhylova, I.O., Matusevych, V.H., Lynnyk, M.I. (2012). Analitychnyy pohlyad na problemu khimiorezystentnoho tuberkulozu: nynishniy stan, dosyahnennya ta deyaki nevyrisheni pytannya [Analytical look to the problem of drug-resistant tuberculosis the present state, achievement and some open question]. Ukrayinskyy pulmonolohichnyy zhurnal, 1, 5-7. [in Ukrainian].

Melnyk, V.M., Prykhodko, A.M., Arefyeva, L.F. (2012). Istoriya vynyknennya i rozvytku khimiorezystentnoho tuberkuliozu v Ukrayini [History of origin and development of drug-resistant tuberculosis is in Ukraine]. Ukrayinskyy pulmonolohichnyy zhurnal, 2, 59-61. [in Ukrainian].

MOZ Ukrayiny. (2014). Nakaz MOZ Ukrayiny vid 04.09.2014 r. № 620 «Unifikovanyy klinichnyy protokol pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy «Tuberkulioz u doroslykh» [Order of MHO of Ukraine from 04.09.2014 № 620 «Сlinical protocol of primary, secondary (specialized) and tertiary (high specialized) medicare is «Compatible «Tuberculosis for adults»]. 1-128. [in Ukrainian].

WHO. (2016). WHO Treatment guidelines for drug-resistant tuberculosis – 2016 update. Geneva, 60.

WHO. (2015). Global tuberculosis control: WHO report 2015. Geneva, Switzerland, 164.

WHO. (2016). Global tuberculosis control: WHO report 2016. Geneva, Switzerland, 214.

Lucenko, I., Riekstina, V., Perevoscikovs, J., Mozgis, D., Khosali, M., Gadoev, J., … & Kumar, A.M.V. (2014). Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006–2010. Public Health Action, 4 (2), 54-58.

Aleksandrina, T.A. (2012). Osoblyvosti epidemiyi tuberkulozu v Ukrayini. [Features of epidemic of tuberculosis are in Ukraine]. Tuberkuloz, lehenevi khvoroby, VIL-Infektsiya, 2, 7-12. [in Ukrainian].

Feschenko, Yu.I., Melnyk, V.M., Matusevych, V.H., Lynnyk, M.I., Novozhylova, I.O., Shtanko, V.L. … & Korotchenko, S.P. (2011). Otsinka kontrolyu za tuberkulozom v Ukrayini za period 2006-2010 roky [Control estimation after tuberculosis in Ukraine for period 2006-2010]. Ukrayinskyy pulmonolohichnyy zhurnal, 4, 5-10. [in Ukrainian].

Kamal, S.M.M., Hossain, A., Sultana, S., Haque, N., Ahmed, J., Rahman, T.M.A. … & Van Deun, A. (2015). Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey. Int. J. Tuberc. Lung Dis, 19 (19), 151-156.

Comolet, T. (2015). Multidrug-resistant tuberculosis: challenges of a global emergence. Bull. WHO, 93 (4), 279-282.

Falzon, D., Gandhi, N., Migliori, G.B., Sotgiu, G., Cox, H.S., Holtz, T.H. … & Menzies, D. (2013). Resistance to fluoroquinolones and secondline injectable drugs: impact on MDR-TB outcomes. Eur. Respir. J., 42 (1), 156-168.

Ukrayina. Cabinet Ministriv. (2011). Pro skhvalennya kontseptsiyi Zahalnoderzhavnoyi tsilovoyi sotsialnoyi prohramy protydiyi zakhvoryuvannyu na tuberkuloz na 2012-2016 roky: rozporyadzhennya Kabinetu Ministriv Ukrayiny vid 30.11.2011 r. [About approval of conception of the National having a special purpose social program of counteraction to the disease on tuberculosis on 2012-2016: of order of Cabinet of Ministers of Ukraine from 30.11.2011 N 1341-р] [in Ukrainian].

Redzwan, M. Rashid Ali, S., Ralph, A.P., Sivaraman Kannan, K.K., William, T. (2015). Individualised second line anti-tuberculous therapy for an extensively resistant pulmonary tuberculosis (XDR PTB) in East Malaysia. Med. J. Malaysia, 70 (3), 200-204.

Prasad, R. (2015). Multidrug resistant tuberculosis treatment in India. Drug Discov. Ther., 9 (3), 156-164.

Villa-Rosas, C., Laniado-Laborín, R., Oceguera-Palao, L. (2015). Primary drug resistance in a region with high burden of tuberculosis: A critical problem. Salud Publica Mex., 57 (2), 177-179.

Sulis, G., Centis, R., Sotgiu, L., D’Ambrosio, L., Pontali, E., Spanevello, A. … & Battista Migliori, G. (2016). Recent developments in the diagnosis and management of tuberculosis. NPJ Prim. Care Respir. Med., 26, 1-8.

Cox, H.S., Isaakidis, P., Varghese, B., Mansoor, H., Ladomirska, J., Saranchuk, P. (2015). The need to accelerate access to new drugs for multidrug–resistant tuberculosis. Bull. WHO, 93 (7), 491-497.

Petrenko, V.I., Protsyuk, R.G. (2015). Problema tuberkulozu v Ukrayini [A problem of tuberculosis is in Ukraine]. Tuberkuloz, lehenevi khvoroby, VIL-Infektsiya, 2 (21), 16-29. [in Ukrainian].

Feshchenko, Yu.I. (2011). Antybiotykorezystentnist mikroorhanizmiv. Stan problemy ta shlyakhi yiyi vyrishennya [The resistance to the antibiotics of microorganisms. State of problem and ways of her decision]. Ukr. khimioterap. zhurn., 4, 41-43. [in Ukrainian].

Nizova, N.M., Golubchikov, M.V. (ed.). (2016). Analitychno–statystychnyy dovidnyk: Tuberkulioz v Ukrayini [Analytically-statistical reference book: Tuberculosis in Ukraine]. Kyiv, 1-141. [in Ukrainian].

Tolstoganov, O.K. (ed.). (2012). Analitychno-statystychnyy dovidnyk za 2000-2011 roky: Tuberkuloz v Ukrayini [Analytically-statistical reference book for period to 2000-2011: Tuberculosis in Ukraine]. Kyiv, 1-98. [in Ukrainian].

Za rivnem zakhvoryuvanosti na tuberkuloz Ukrayina sioma v Yevropi [After the level of morbidity on tuberculosis Ukraine is seventh in Europe]. [E-resource]. (2011). Retrieved from: http: //provolyn.com/news_2011–11–16/12659–za–rivnem–zahvoryuvanosti–na–tuberkulozukrayina–soma–v–ievropi.html. [in Ukrainian].

Barbova, A.I., Hayova, L.V., Zhurilo, O.A., Trofimova, P.S., Aliyeva N.M. (2015). Vykorystannya novoyi molekulyarno-henetychnoyi systemy GenoType i ridkoho zhyvylnoho seredovyshcha dlya shvydkoyi diahnostyky tuberkulozu [The use of the new molecular-genetic system GenoType and liquid nourishing environment is for rapid diagnostics of tuberculosis]. Science Rise, 10/3 (15), 29-36. [in Ukrainian].

Barbova, A.I. (2016). Sovremennyie podhody k diagnostike multirezistentnogo tuberkuleza [Modern going near diagnostics of multidrug-resistant tuberculosis]. Aktualni pitannya vedennya hvorykh na khimiorezystentny tuberkulioz na statsionarnomu ta ambulatornomu etapakh: materialy naukovo–praktyhnoyi konferentsiyi (Kyiv). Ukrayinskyy pulmonolohichnyy zhurnal, 2, 28-29. [in Russian].

Barbova, A.I. , Cherenko, S.O., Starychek, H.V., Avramchuk, O.V., Pohrebna, M.V., Aliyeva, N.M. (2016). Varianty mono- i polirezystentnosti MBT do protytuberkulioznykh preparativ I ryadu u khvorykh z novymy i povtornymy vypadkamy tuberkuliozu [Variants mono- and polyresistanse of MBT to first line anti-mycobacterial drugs for patients with the new and repeated cases of tuberculosis]. Tuberkuloz. Lehenevi khvoroby. VIL-Infektsiya, 1 (24), 23-26. [in Ukrainian].

Downloads

Published

2017-12-29

How to Cite

Feshchenko, Y. I., Lytvynenko, N. A., Varytska, H. O., Chobotar, O. P., Pohrebna, M. V., Senko, Y. O., … Hrankina, N. (2017). PROSPECTS FOR IMPROVING THE TREATMENT EFFICACY FOR PATIENTS WITH MULTIDRUG RESISTANT TUBERCULOSIS: GLOBAL TRENDS AND NATIONAL ADVANCES. Infectious Diseases – Infektsiyni Khvoroby, (4), 10–21. https://doi.org/10.11603/1681-2727.2017.4.8418

Issue

No. 4 (2017)

Section

Original investigations

License

Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration

Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes

 Лицензия Creative Commons

This journal is available through Creative Commons (CC) License  BY-NC "Attribution-NonCommercial" 4.0